<DOC>
	<DOCNO>NCT02560519</DOCNO>
	<brief_summary>Colloid solution widely use volume replacement therapy high oncotic pressure , could reduce interstitial fluid shift . Human albumin colloid solution biologic origin molecular weight 60 kDa . As abundant plasma protein , physiological importance well-being endothelial glycocalyx . Older study septic patient , however , show benefit albumin saline solution . Crystalloid solution , Ringer 's acetate , impair neither renal function coagulation , volume expand effect questionable . For several reason ( use heart-lung machine , systemic inflammation , coagulation disturbance ) , patient undergo cardiac surgery need especially large amount fluid . However , large trial compare albumin solution crystalloid solution cardiac surgery . This double-blinded trial randomize accord power analysis 1250 cardiac surgery patient ( =625+625 ) Meilahti hospital use either 4 % Albumin Ringer 's acetate solution prim heart-lung machine perioperative volume replacement therapy . The primary efficacy safety endpoint study incidence major adverse event ( MAE ) , define composite endpoint all-cause mortality , acute myocardial infarction , acute heart failure low output syndrome , resternotomy , stroke , certain arrhythmia , major bleeding , infection compromise post-procedural rehabilitation , acute kidney injury within 90 day postoperatively . The secondary outcome total number MAEs , major adverse cardiac event ( MACE ) , perioperative fluid balance , blood product transfusion , blood loss , acute kidney injury , day alive without mechanical ventilation/outside ICU/at home 90 day well 90-day mortality . Blood sample biochemical analysis collect four perioperative time point . This trial provide data efficacy safety 4 % albumin cardiac surgery patient . The biochemical mechanism albumin assess .</brief_summary>
	<brief_title>Albumin Cardiac Surgery</brief_title>
	<detailed_description>The use cardiopulmonary bypass ( CPB ) two study solution : albumin solution final concentration 4 % Ringer 's acetate solution . The trial consist two phase follow . For patient , one study solution use phase trial accord randomization . In first phase trial , study solution use prim CPB tubing . The CPB priming volume comprise study solution . See Blinding section detail . - Albumin group ( trial group ) : A mixture 20 % ( 200 mg/mL ) albumin solution ( Albuman® 200 g/L , Sanquin , Netherlands ) Ringer 's acetate solution ( see ) final albumin concentration 4 % . - Ringer group ( conventional group ) : Ringer 's acetate solution ( Ringer-acetate® , Baxter ; pH 6.0 , content Na+ 131 mmol/L , Cl- 112 mmol/L , acetate 30 mmol/L ) alone . In second phase trial , surgery first 24 hour ICU treatment , study solution use 4000 mL volume replacement therapy . Ringer 's acetate solution use thereafter , i.e . 4000 mL need volume replacement therapy second study phase . The volume replacement therapy protocolled base clinical decision . Albumin group ( trial group ) :4 % ( 40 mg/mL ) albumin ( Albuman® , Sanquin , Netherlands ) •Ringer group ( conventional group ) : Ringer 's acetate solution ( Ringer-acetate® , Baxter ; pH 6.0 , content Na+ 131 mmol/L , Cl- 112 mmol/L , acetate 30 mmol/L ) The trial end first 24 hour ICU treatment patient leave ICU latter occurs within first postoperative 24 hour . After study period , fluid administer accord local clinical practice . The use blood product , exclude albumin , protocolled , base clinical decision . For physiological basic need fluid , Ringer 's acetate solution give throughout study period , i.e . surgery postoperatively , background infusion 1 ml/kg/h , round near multible 10 ml .</detailed_description>
	<mesh_term>Pharmaceutical Solutions</mesh_term>
	<criteria>follow primary repeat open heart surgery procedure , either independently combination : CABG , aortic valve replacement/repair , mitral valve replacement/repair , tricuspid valve replacement/repair , MAZE procedure modification , surgery aortic root ascend aorta require hypothermic circulatory arrest ; schedule elective surgery operate index admission immediate emergency surgery ( i.e . time recruitment ) endstage kidney disease ( estimate GFR &lt; 20 mL/min base serum/ plasma creatinine ) hemophilia A , hemophilia B patient denial use blood product derivatives blood product ticagrelor prasugrel treatment within 2 day clopidogrel within 3 day preoperatively apixaban rivaroxaban treatment within 2 day dabigatran within 4 day</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>90 Years</maximum_age>
	<verification_date>October 2016</verification_date>
	<keyword>human serum albumin solution</keyword>
	<keyword>Cardiopulmonary Bypass</keyword>
</DOC>